Abstract:Background: CD47-targeted immune checkpoint inhibitors have shown potent anti-tumor efficacy in several malignant tumors. However, glioblastoma, one of the most malignant brain tumors in the central nervous system (CNS), was still a challenge for CD47-targeted immunotherapy. Methods: SIRPα-Fc, a CD47-targeted fusion protein, was employed to investigate the anti-tumor efficacy of blocking CD47-SIRPα axis alone or combined with autophagy depletion in glioblastoma. Confocal microscopy, transmission electron microscopy and western blot were used to detect autophagy. Glioblastoma xenograft tumors were established to investigate the synergistic anti-tumor effect of simultaneously blocking CD47-SIRPα axis and autophagy in glioblastoma. Syngeneic immunocompetent glioblastoma models were established to detect the role of adaptive immune response in SIRPα-Fc-treated glioblastoma. Results: SIRPα-Fc has potent anti-glioblastoma efficacy via increasing macrophages phagocytosis and cytotoxicity against glioblastoma cells. Meanwhile, autophagy and autophagic flux were markedly triggered by SIRPα-Fc in glioblastoma cells through inactivation of Akt/mTOR. Importantly, abolishment of the autophagy by pharmacological inhibitors or siRNA enhanced SIRPα-Fc-induced macrophage phagocytosis and cytotoxicity against glioblastoma cells. Simultaneously blocking CD47-SIRPα axis and autophagy increased macrophages infiltration and tumor cell apoptosis, eliciting enhanced anti-glioblastoma efficacy and prolonged survival of tumor-bearing mice compared with treatment with SIRPα-Fc alone. Furthermore, adaptive immune responses, mainly including CD8+ T cells, were also involved in the anti-glioblastoma efficacy of SIRPα-Fc. Conclusions: Our data revealed that SIRPα-Fc could elicit potent anti-glioblastoma efficacy, combined with autophagy inhibition significantly enhanced the anti-glioblastoma efficacy, which highlighted a potential therapeutic approach for glioblastoma through disrupting CD47-SIRPα axis alone or combined with autophagy depletion. Legal entity responsible for the study: Fudan University Funding: None Disclosure: All authors have declared no conflicts of interest.

A Notch inhibitor plus Resveratrol induced blockade of autophagy drives glioblastoma cell death by promoting a switch to apoptosis

Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists

Cdk4 Regulates Glioblastoma Cell Invasion and Stemness and Is Target of a Notch Inhibitor Plus Resveratrol Combined Treatment

Enhanced Proliferation Inhibition and Apoptosis in Glioma Cells Elicited by Combination of Irinotecan and Imatinib

NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma

Dddr-39. Pi3 Kinase And Checkpoint Inhibition: A Potentially Novel Therapeutic Strategy For Glioblastoma (Gbm)

Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells

Combination of microRNA and suicide gene for targeting Glioblastoma: Inducing apoptosis and significantly suppressing tumor growth in vivo

Combining an Autophagy Inhibitor, MPT0L145, with Abemaciclib Is a New Therapeutic Strategy in GBM Treatment

Regorafenib Induces Lethal Autophagy Arrest by Stabilizing PSAT1 in Glioblastoma

Resveratrol as an antitumor agent for glioblastoma multiforme: Targeting resistance and promoting apoptotic cell deaths

Abstract LB537: CDK4/6 inhibition enhances oncolytic efficacy on refractory glioblastoma by potentiating tumor-selective cell killing and T cell activation

Novel and Promising Therapeutic Approaches for Glioblastoma: Blocking CD47-SIRPα Axis Alone or Combined with Autophagy Depletion

Resveratrol Impairs Glioma Stem Cells Proliferation and Motility by Modulating the Wnt Signaling Pathway

Focus on the Use of Resveratrol as an Adjuvant in Glioblastoma Therapy

Simultaneous Interference with HER1/EGFR and RAC1 Signaling Drives Cytostasis and Suppression of Survivin in Human Glioma Cells in Vitro

A Selective Histone Deacetylase Inhibitor Induces Autophagy and Cell Death via SCNN1A Downregulation in Glioblastoma Cells

Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma

Enhanced Efficacy of Histone Deacetylase Inhibitor Panobinostat Combined with Dual PI3K/mTOR Inhibitor BEZ235 Against Glioblastoma

The Combination of 5-FU and Resveratrol Can Suppress the Growth of Glioblastoma Cells Through Downregulation of TRPM2 and β-Catenin

Saikosaponin D Inducing Apoptosis and Autophagy through the Activation of Endoplasmic Reticulum Stress in Glioblastoma